DMAC News and Press, DiaMedica Therapeutics Inc. From 09/14/20

DiaMedica Therapeutics ( DMAC +4.2% ) announced dosing of the first participants in the diabetic kidney disease cohort of the REDUX Phase II Chronic Kidney Disease study. More news on: DiaMedica Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for chronic kidney disease, today announced dosing of the first participants in the diabetic kidney disease (DKD) cohort of the REDUX Phase II Chronic Kidney Disease (CKD) stud...

DiaMedica Therapeutics Inc. (DMAC) Q2 2020 Earnings Conference Call August 12, 2020 08:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer Scott Kellen - Chief Financial Officer Harry Alcorn - Chief Medical Officer Conference Call Participants Alex...

DiaMedica Therapeutics (NASDAQ: DMAC ) : Q2 GAAP EPS of -$0.17 misses by $0.02 . More news on: DiaMedica Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

DiaMedica Completes $23M Public Offering of Common Shares Diabetic Kidney Disease Cohort Added to REDUX Study Post-Offering Cash and Investments of $32.9 Million Providing Expected Two-Year Runway Conference Call with Management Tomorrow, August 12 at 7am CT ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the closing of its previously announced underwritten registered public offering of 4,600,000 of its common shares, including 600,000 shares sold upon full exercise of the underwriters’ o...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2020 financial results will be released after the markets close on Tuesday, August 11 th . DiaMedica will host a live conference call on Wednesday, August 12 th at 7:00 AM Central Time to discuss its business ...

DiaMedica Therapeutics (NASDAQ: DMAC )   -12.9%  premarket, after the company prices its previously announced public offering of 4M shares at $5/share for gross proceeds of $20M. More news on: DiaMedica Therapeutics Inc., Stocks on the move, , Healthcare stocks news, Read ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of the previously announced underwritten registered public offering of 4,000,000 of its common shares at a price to the public of $5.00 per share. DiaMedica has also granted the und...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today that it intends to offer and sell its common shares in an underwritten public offering. In addition, DiaMedica intends to grant the underwriters a 30-day option to purchase up to an additional ...